John G Ullman & Associates Inc. Purchases Shares of 1,874 Boston Scientific Corporation $BSX

John G Ullman & Associates Inc. acquired a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, Holdings Channel.com reports. The fund acquired 1,874 shares of the medical equipment provider’s stock, valued at approximately $201,000.

A number of other institutional investors and hedge funds have also modified their holdings of BSX. Vanguard Group Inc. boosted its stake in Boston Scientific by 1.3% during the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock worth $13,577,311,000 after buying an additional 1,697,945 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Boston Scientific by 18.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock worth $1,070,387,000 after acquiring an additional 1,664,108 shares during the period. Swedbank AB boosted its position in shares of Boston Scientific by 114.5% during the 2nd quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider’s stock valued at $302,816,000 after acquiring an additional 1,505,019 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Boston Scientific by 10.8% in the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock worth $1,426,779,000 after purchasing an additional 1,383,524 shares in the last quarter. Finally, Ninety One UK Ltd lifted its stake in Boston Scientific by 33.5% during the second quarter. Ninety One UK Ltd now owns 5,146,218 shares of the medical equipment provider’s stock worth $552,755,000 after purchasing an additional 1,290,414 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig sold 4,000 shares of the firm’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the transaction, the director owned 18,479 shares in the company, valued at $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $18,659,923.46. The trade was a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock valued at $17,972,457 over the last ninety days. Company insiders own 0.50% of the company’s stock.

Boston Scientific Trading Up 1.5%

BSX stock opened at $99.20 on Monday. The business has a fifty day moving average price of $101.29 and a 200 day moving average price of $101.77. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $109.50. The stock has a market capitalization of $146.99 billion, a price-to-earnings ratio of 59.05, a P/E/G ratio of 2.39 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter in the prior year, the business earned $0.62 earnings per share. The business’s revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Needham & Company LLC reiterated a “buy” rating and issued a $121.00 price objective on shares of Boston Scientific in a research note on Friday. UBS Group boosted their price target on Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Thursday, July 24th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $125.00 price target on shares of Boston Scientific in a research report on Monday, September 29th. Leerink Partners increased their price objective on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. Finally, Erste Group Bank downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Boston Scientific presently has a consensus rating of “Buy” and an average price target of $120.71.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.